Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics of Docetaxel or Gemcitabine in NSCLC and Breast Cancer
NCT00695994Phase 2Completed
- Sponsor
- National University Hospital
- Start
- Oct 2006
- Primary completion
- Sep 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel, gemcitabine and carboplatin in non-small cell lung cancer (NSCLC) and breast cancer (2 arms), sponsored by National University Hospital. Primary endpoint: Treatment toxicities at 36 weeks. Started Oct 2006; status: completed.
02
Drugs
docetaxelgemcitabinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT00695994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00695994.